Showing 7901-7910 of 8648 results for "".
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- Stoke Therapeutics Presents Preclinical Data on Potential Treatment For Inherited Optic Nerve Disorderhttps://modernod.com/news/stoke-therapeutics-presents-preclinical-data-on-potential-treatment-for-inherited-optic-nerve-disorder/2477751/Stoke Therapeutics announced new preclinical data demonstrating in-vitro and in-vivo target engagement and protein upregulation in OPA1 protein-deficient cells. OPA1 protein deficiency is the primary cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorde
- US Physician Survey Illustrates the Impact of Thyroid Eye Disease on Patient Quality of Lifehttps://modernod.com/news/us-physician-survey-illustrates-the-impact-of-thyroid-eye-disease-on-patient-quality-of-life/2477745/Horizon Therapeutics announced results of a US physician survey showing that endocrinologists and ophthalmologists perceive thyroid eye disease (TED) to have a significant burden on their patients’ quality of life. The analysis was accepted as a poster presentation at the AACE 29th Ann
- Optogenetic Gene Therapy Well Tolerated For Retinitis Pigmentosahttps://modernod.com/news/optogenetic-gene-therapy-well-tolerated-for-retinitis-pigmentosa/2477737/New findings presented on ARVOLearn showed that an optogenetic gene therapy was well tolerated in a group of patients with end-stage non-syndromic retinitis pigmentosa, according to a
- Visual Impairment Tied to Increased Dementia Risk in Older Womenhttps://modernod.com/news/visual-impairment-tied-to-increased-dementia-risk-in-older-women/2477730/Older women with objective visual impairment are likely to develop dementia or mild cognitive impairment, a secondary analysis of data from the Women’s Health Initiative (WHI) suggests, according to a Reuters report. Researche
- Hydroxychloroquine Fails to Help Hospitalized Coronavirus Patients in US Funded Studyhttps://modernod.com/news/hydroxychloroquine-fails-to-help-hospitalized-coronavirus-patients-in-us-funded-study/2477728/Hydroxychloroquine, a decades-old malaria drug, didn’t appear to help hospitalized patients with COVID-19, according to a new observational study published Thursday in the New England Journal of Medicine, according to a CN
- Oculis to Present Results From Its Phase 2 Trial of OCS-01 for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-to-present-results-from-its-phase-2-trial-of-ocs-01-for-inflammation-and-pain-following-cataract-surgery/2477721/Oculis announces that it will present results from its phase 2 (SKYGGN) clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, at the American Society of Cataract and Refractive Surgery (ASCRS) annual
- Mystery Inflammatory Syndrome In Kids And Teens Likely Linked To COVID-19https://modernod.com/news/mystery-inflammatory-syndrome-in-kids-and-teens-likely-linked-to-covid-19/2477722/Sixty-four children and teens in New York State are suspected of having a mysterious inflammatory syndrome that is believed to be linked to COVID-19, the New York Department of Health said in an alert issued Wednesday, as
- Bausch + Lomb Licenses Exclusive Rights To a Biosimilar Candidate for Lucentis (Ranibizumab) in the US and Canadahttps://modernod.com/news/bausch-lomb-licenses-exclusive-rights-to-a-biosimilar-candidate-for-lucentis-ranibizumab-in-the-us-and-canada/2477718/Bausch + Lomb has entered into an exclusive licensing agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, a Nordic biosimilar developer, to develop and commercialize a biosimilar candidate to Lucentis (ranibizumab) in the United States and Canada. The companies
- UK Surpasses Italy In Recorded Coronavirus Deaths, Now Leads Europe In Fatalitieshttps://modernod.com/news/uk-surpasses-italy-in-recorded-coronavirus-deaths-now-leads-europe-in-fatalities/2477715/Over 32,000 people have died from the new coronavirus in the United Kingdom, according to the Office for National Statistics, marking the first time in the pandemic that it has led Europe in the number of deaths, according to an NPR